BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 24886747)

  • 1. Modelling the impact of ivermectin on River Blindness and its burden of morbidity and mortality in African Savannah: EpiOncho projections.
    Turner HC; Walker M; Churcher TS; Basáñez MG
    Parasit Vectors; 2014 May; 7():241. PubMed ID: 24886747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reaching the london declaration on neglected tropical diseases goals for onchocerciasis: an economic evaluation of increasing the frequency of ivermectin treatment in Africa.
    Turner HC; Walker M; Churcher TS; Osei-Atweneboana MY; Biritwum NK; Hopkins A; Prichard RK; Basáñez MG
    Clin Infect Dis; 2014 Oct; 59(7):923-32. PubMed ID: 24944228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modelling the elimination of river blindness using long-term epidemiological and programmatic data from Mali and Senegal.
    Walker M; Stolk WA; Dixon MA; Bottomley C; Diawara L; Traoré MO; de Vlas SJ; Basáñez MG
    Epidemics; 2017 Mar; 18():4-15. PubMed ID: 28279455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elimination of transmission of onchocerciasis (river blindness) with long-term ivermectin mass drug administration with or without vector control in sub-Saharan Africa: a systematic review and meta-analysis.
    Mutono N; Basáñez MG; James A; Stolk WA; Makori A; Kimani TN; Hollingsworth TD; Vasconcelos A; Dixon MA; de Vlas SJ; Thumbi SM
    Lancet Glob Health; 2024 May; 12(5):e771-e782. PubMed ID: 38484745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ivermectin for onchocercal eye disease (river blindness).
    Ejere HO; Schwartz E; Wormald R; Evans JR
    Cochrane Database Syst Rev; 2012 Aug; 2012(8):CD002219. PubMed ID: 22895928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential impact of moxidectin on onchocerciasis elimination in Africa: an economic evaluation based on the Phase II clinical trial data.
    Turner HC; Walker M; Attah SK; Opoku NO; Awadzi K; Kuesel AC; Basáñez MG
    Parasit Vectors; 2015 Mar; 8():167. PubMed ID: 25889256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population biology of human onchocerciasis.
    Basáñez MG; Boussinesq M
    Philos Trans R Soc Lond B Biol Sci; 1999 Apr; 354(1384):809-26. PubMed ID: 10365406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Taking the strain out of onchocerciasis? A reanalysis of blindness and transmission data does not support the existence of a savannah blinding strain of onchocerciasis in West Africa.
    Cheke RA; Little KE; Young S; Walker M; Basáñez MG
    Adv Parasitol; 2021; 112():1-50. PubMed ID: 34024357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uncertainty surrounding projections of the long-term impact of ivermectin treatment on human onchocerciasis.
    Turner HC; Churcher TS; Walker M; Osei-Atweneboana MY; Prichard RK; Basáñez MG
    PLoS Negl Trop Dis; 2013; 7(4):e2169. PubMed ID: 23634234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human Onchocerciasis: Modelling the Potential Long-term Consequences of a Vaccination Programme.
    Turner HC; Walker M; Lustigman S; Taylor DW; Basáñez MG
    PLoS Negl Trop Dis; 2015; 9(7):e0003938. PubMed ID: 26186715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The burden of skin disease and eye disease due to onchocerciasis in countries formerly under the African Programme for Onchocerciasis Control mandate for 1990, 2020, and 2030.
    Vinkeles Melchers NVS; Stolk WA; van Loon W; Pedrique B; Bakker R; Murdoch ME; de Vlas SJ; Coffeng LE
    PLoS Negl Trop Dis; 2021 Jul; 15(7):e0009604. PubMed ID: 34310602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can mass drug administration of moxidectin accelerate onchocerciasis elimination in Africa?
    Kura K; Milton P; Hamley JID; Walker M; Bakajika DK; Kanza EM; Opoku NO; Howard H; Nigo MM; Asare S; Olipoh G; Attah SK; Mambandu GL; Kennedy KK; Kataliko K; Mumbere M; Halleux CM; Hopkins A; Kuesel AC; Kinrade S; Basáñez MG
    Philos Trans R Soc Lond B Biol Sci; 2023 Oct; 378(1887):20220277. PubMed ID: 37598705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elimination of onchocerciasis from Colombia: first proof of concept of river blindness elimination in the world.
    Nicholls RS; Duque S; Olaya LA; López MC; Sánchez SB; Morales AL; Palma GI
    Parasit Vectors; 2018 Apr; 11(1):237. PubMed ID: 29642939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. River Blindness: Mathematical Models for Control and Elimination.
    Basáñez MG; Walker M; Turner HC; Coffeng LE; de Vlas SJ; Stolk WA
    Adv Parasitol; 2016; 94():247-341. PubMed ID: 27756456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does Increasing Treatment Frequency Address Suboptimal Responses to Ivermectin for the Control and Elimination of River Blindness?
    Frempong KK; Walker M; Cheke RA; Tetevi EJ; Gyan ET; Owusu EO; Wilson MD; Boakye DA; Taylor MJ; Biritwum NK; Osei-Atweneboana M; Basáñez MG
    Clin Infect Dis; 2016 Jun; 62(11):1338-1347. PubMed ID: 27001801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What does the COVID-19 pandemic mean for the next decade of onchocerciasis control and elimination?
    Hamley JID; Blok DJ; Walker M; Milton P; Hopkins AD; Hamill LC; Downs P; de Vlas SJ; Stolk WA; Basáñez MG
    Trans R Soc Trop Med Hyg; 2021 Mar; 115(3):269-280. PubMed ID: 33515042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxycycline plus ivermectin versus ivermectin alone for treatment of patients with onchocerciasis.
    Abegunde AT; Ahuja RM; Okafor NJ
    Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD011146. PubMed ID: 26771164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of long-term treatment of onchocerciasis with ivermectin in Kaduna State, Nigeria: first evidence of the potential for elimination in the operational area of the African Programme for Onchocerciasis Control.
    Tekle AH; Elhassan E; Isiyaku S; Amazigo UV; Bush S; Noma M; Cousens S; Abiose A; Remme JH
    Parasit Vectors; 2012 Feb; 5():28. PubMed ID: 22313631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How does onchocerciasis-related skin and eye disease in Africa depend on cumulative exposure to infection and mass treatment?
    Vinkeles Melchers NVS; Stolk WA; Murdoch ME; Pedrique B; Kloek M; Bakker R; de Vlas SJ; Coffeng LE
    PLoS Negl Trop Dis; 2021 Jun; 15(6):e0009489. PubMed ID: 34115752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Required duration of mass ivermectin treatment for onchocerciasis elimination in Africa: a comparative modelling analysis.
    Stolk WA; Walker M; Coffeng LE; Basáñez MG; de Vlas SJ
    Parasit Vectors; 2015 Oct; 8():552. PubMed ID: 26489937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.